1. Home
  2. OGEN vs VRAX Comparison

OGEN vs VRAX Comparison

Compare OGEN & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.74

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.25

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGEN
VRAX
Founded
1996
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
2.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
OGEN
VRAX
Price
$0.74
$0.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
911.2K
260.1K
Earning Date
03-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,986.00
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.26
52 Week High
$18.90
$2.29

Technical Indicators

Market Signals
Indicator
OGEN
VRAX
Relative Strength Index (RSI) 35.71 31.96
Support Level $0.77 $0.26
Resistance Level $0.84 $0.29
Average True Range (ATR) 0.07 0.02
MACD -0.01 0.00
Stochastic Oscillator 4.00 6.74

Price Performance

Historical Comparison
OGEN
VRAX

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Share on Social Networks: